NASDAQ:AXSM Axsome Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Axsome Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $77.02 +1.09 (+1.44 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$76.01Now: $77.02▼$79.9350-Day Range$68.34MA: $76.78▼$83.0652-Week Range$13.64Now: $77.02▼$109.94Volume299,976 shsAverage Volume712,890 shsMarket Capitalization$2.87 billionP/E RatioN/ADividend YieldN/ABeta2.81 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $149.56, Axsome Therapeutics has a forecasted upside of 94.2% from its current price of $77.02.Amount of Analyst CoverageAxsome Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAxsome Therapeutics has received 343 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAxsome Therapeutics has received 290 “underperform” votes. (Add your “underperform” vote.)Community SentimentAxsome Therapeutics has received 54.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote “Outperform” if you believe AXSM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $110,574.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 26.00% of the stock of Axsome Therapeutics is held by insiders.Percentage Held by Institutions63.71% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to decrease in the coming year, from ($2.59) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -29.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -29.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 14.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.04 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM Previous Symbol CUSIPN/A CIK1579428 Webaxsome.com Phone212-332-3241Debt Debt-to-Equity Ratio0.09 Current Ratio8.30 Quick Ratio8.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.18 per share Price / Book14.87Profitability EPS (Most Recent Fiscal Year)($2.01) Net Income$-68,350,000.00 Net MarginsN/A Return on Equity-76.42% Return on Assets-57.97%Miscellaneous Employees29 Outstanding Shares37,284,000Market Cap$2.87 billion Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $77.02 +1.09 (+1.44 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AXSM News and Ratings via Email Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions How has Axsome Therapeutics' stock price been impacted by Coronavirus? Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXSM shares have increased by 4.6% and is now trading at $77.02. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Axsome Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axsome Therapeutics. When is Axsome Therapeutics' next earnings date? Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Axsome Therapeutics. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics Inc (NASDAQ:AXSM) announced its quarterly earnings data on Monday, August, 10th. The company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.05. View Axsome Therapeutics' earnings history. What price target have analysts set for AXSM? 10 brokers have issued twelve-month price objectives for Axsome Therapeutics' stock. Their forecasts range from $95.00 to $210.00. On average, they expect Axsome Therapeutics' stock price to reach $149.56 in the next year. This suggests a possible upside of 94.2% from the stock's current price. View analysts' price targets for Axsome Therapeutics. Who are some of Axsome Therapeutics' key competitors? Some companies that are related to Axsome Therapeutics include GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Ascendis Pharma A/S (ASND), CureVac B.V. (CVAC), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Mirati Therapeutics (MRTX), Myokardia (MYOK), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO) and Bausch Health Companies (BHC). View all competitors. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Bristol-Myers Squibb (BMY), Micron Technology (MU), AbbVie (ABBV), Gilead Sciences (GILD) and Pfizer (PFE). Who are Axsome Therapeutics' key executives? Axsome Therapeutics' management team includes the following people: Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)Joseph Debrah-Afful, Director of Fin. When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.19%), RTW Investments LP (4.45%), Alethea Capital Management LLC (2.72%), FMR LLC (1.54%), Goldman Sachs Group Inc. (1.12%) and Stifel Financial Corp (1.09%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View institutional ownership trends for Axsome Therapeutics. Which institutional investors are selling Axsome Therapeutics stock? AXSM stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Cormorant Asset Management LP, EAM Investors LLC, Nicholas Investment Partners LP, Moody Aldrich Partners LLC, Driehaus Capital Management LLC, Trexquant Investment LP, and Federated Hermes Inc.. View insider buying and selling activity for Axsome Therapeutics. Which institutional investors are buying Axsome Therapeutics stock? AXSM stock was purchased by a variety of institutional investors in the last quarter, including RTW Investments LP, Vanguard Group Inc., WMS Partners LLC, FMR LLC, Avidity Partners Management LP, Goldman Sachs Group Inc., CWM LLC, and Perceptive Advisors LLC. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, and Nick Pizzie. View insider buying and selling activity for Axsome Therapeutics. How do I buy shares of Axsome Therapeutics? Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $77.02. How big of a company is Axsome Therapeutics? Axsome Therapeutics has a market capitalization of $2.87 billion. The company earns $-68,350,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe. What is Axsome Therapeutics' official website? The official website for Axsome Therapeutics is axsome.com. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company can be reached via phone at 212-332-3241. This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
